Trastuzumab Deruxtecan

Antibody–drug conjugate

Also known as DS-8201

Approvedregulatory verdict

Evidence outlook

Approved: Non-Small Cell Lung Cancer, HR+/HER2- Metastatic Breast Cancer (label: HER2-low and HER2-ultralow metastatic breast cancer, HR-positive or HR-negative, after prior...), Breast Cancer, HER2-Positive Breast Cancer

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Partial signal

Also approved (4)
US
  • HER2-Low and HER2-Ultralow Metastatic Breast Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with unresectable or metastatic Hormone receptor (HR)-positive HER2-low (IHC 1+ or IHC 2+/ISH-) or HER2-ultralow (IHC 0 with membrane staining) breast cancer, as determined by an FDA-authorized test, that has progressed on one or more endocrine therapies in the metastatic setting [see Dosage and Administration (2.1) ] . HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer, as determined by an FDA-authorized test, who have received a prior chemotherapy in the metastatic settin
  • HER2-Positive Locally Advanced or Metastatic Gastric Cancer ENHERTU, as monotherapy, is indicated for the treatment of adult patients with locally advanced or metastatic HER2-positive (IHC 3+ or IHC 2+/ISH positive) gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received a prior trastuzumab-based regimen.
Product first approved 2019FDA label
EU
  • Enhertu (with pertuzumab): 1st-line treatment of adult patients with unresectable or metastatic HER2-positive breast cancerastrazeneca.com
  • Breast cancerHER2-positive breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received one or more prior anti-HER2-based regimens.HER2-low and HER2-ultralow breast cancerEnhertu as monotherapy is indicated for the treatment of adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-low or HER2-ultralow breast cancer who have received at least one endocrine therapy in the metastatic setting and who are not considered suitable for endocrine therapy as the next...
    EMA
Product first approved 2021

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.

Phase 3 (23)
Breast Cancer
HER2-Positive Breast Cancer
NCT07578116 · SWOG Cancer Research Network
2027-03-09 – 2033-05-31 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic HER2-Positive Breast Carcinoma, Oligometastatic Breast Carcinoma
What this study did
NCT04739761 · AstraZeneca
2021-06-22 – 2027-05-26 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07828054 · Mario Negri Institute for Pharmacological Research
2026-12-20 – 2030-12-20 · Breast Cancer, Interstitial Lung Disease (ILD)
What this study did
NCT07683754 · Daiichi Sankyo
2026-11-04 – 2030-08-28 · Advanced Breast Cancer, Metastatic Breast Cancer, HER2 Positive, HR Positive
What this study did
NCT06585969 · Danish Breast Cancer Cooperative Group
2026-01-01 – 2026-01-01 · Metastatic Breast Cancer, ER-positive Breast Cancer, Luminal B, Her2 Enriched, Basal Like
What this study did
Non-Small Cell Lung Cancer
NCT05048797 · AstraZeneca
2021-10-28 – 2027-07-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT07022483 · Daiichi Sankyo
2025-09-30 – 2032-03-23 · Endometrial Cancer
What this study did
NCT06764875 · AstraZeneca
2025-03-01 – 2030-12-09 · HER2-positive Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
What this study did
NCT06731478 · Daiichi Sankyo
2025-02-27 – 2030-02-01 · Gastric Cancer, Gastroesophageal Junction Cancer
What this study did
NCT06467357 · AstraZeneca
2024-08-12 – 2029-05-16 · Biliary Tract Cancer
What this study did
NCT06174987 · Daiichi Sankyo
2024-01-05 – 2028-02-17 · Advanced Cancer, Metastatic Cancer
What this study did
NCT04704934 · Daiichi Sankyo
2021-05-21 – 2026-08-31 · Gastric Cancer, Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 2 (70)
Breast Cancer
NCT07393425 · Shanghai Jiao Tong University School of Medicine
2026-02-02 – 2032-09-30 · HER2 + Breast Cancer
What this study did
NCT07905313 · Azienda Ospedaliero-Universitaria Careggi
2027-05-15 – 2030-12-31 · Breast Cancer (Advanced/Metastatic)
What this study did
NCT05704829 · Women's Cancer Study Group GmbH
2024-02-05 – 2030-09 · HER2-positive Early Breast Cancer
What this study did
NCT07371585 · SOLTI Breast Cancer Research Group
2026-02-18 – 2030-07-01 · Breast Cancer Stage IV
What this study did
NCT07836257 · Fujian Medical University
2026-10-10 – 2029-10-30 · Breast Cancer
What this study did
NCT07151586 · UNICANCER
2026-09 – 2029-10 · Triple Negative Breast Neoplasms, Neoplasm Metastasis, HER 2 Low-expressing Breast Cancer
What this study did
NCT06733233 · Guangzhou Women and Children's Medical Center
2025-01-01 – 2029-01-01 · Breast Cancer, Estrogen Receptor-Positive, HER2 Low Breast Cancer
What this study did
NCT05953168 · Fudan University
2023-08 – 2026-08 · Triple-Negative Breast Cancer
What this study did
NCT05744375 · Spanish Breast Cancer Research Group
2023-09-28 – 2025-07-17 · Locally Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT06439693 · Dana-Farber Cancer Institute
2024-08-08 – 2033-03-30 · Breast Cancer Female, Breast Cancer, Breast Cancer Metastatic, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Stage IV Breast Cancer
What this study did
NCT05795101 · Filipa Lynce, MD
2023-05-04 – 2032-12-01 · Invasive Breast Cancer, Inflammatory Breast Cancer Stage III, HER2-positive Breast Cancer, HER2 Low Breast Adenocarcinoma, Breast Cancer
What this study did
NCT05900206 · Karolinska University Hospital
2023-10-26 – 2032-04-30 · Breast Cancer
What this study did
NCT07459673 · Memorial Sloan Kettering Cancer Center
2026-03-04 – 2030-03-04 · Breast Cancer, HER2-positive Breast Cancer, Breast Cancer Stage IV
What this study did
NCT06172127 · MedSIR
2024-07-22 – 2029-06 · HER2-positive Breast Cancer
What this study did
NCT06548178 · Fudan University
2024-09 – 2028-09 · HER2-positive Breast Cancer
What this study did
NCT05710666 · Cancer Trials Ireland
2023-10-26 – 2028-03-30 · HER2-positive Breast Cancer
What this study did
NCT06797622 · Fudan University
2025-02-15 – 2027-04-15 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT06088056 · Fudan University
2023-11 – 2026-07 · Breast Cancer, Brain Metastases, Radiotherapy
What this study did
NCT04539938 · Seagen, a wholly owned subsidiary of Pfizer
2020-12-01 – 2025-03-07 · HER2 Positive Breast Cancer
What this study did
NCT04752059 · Medical University of Vienna
2020-07-28 – 2023-05-01 · Breast Cancer Stage IV
What this study did
NCT04420598 · MedSIR
2020-05-25 – 2023-04-04 · Advanced Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Leptomeningeal Metastasis
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT06533826 · Ana C Garrido-Castro, MD
2024-10-29 – 2038-08-01 · Breast Cancer, HER2-low Breast Cancer, Metastatic Breast Cancer, HER2-negative Breast Cancer
What this study did
NCT05982678 · The Netherlands Cancer Institute
2024-05-02 – 2034-10-01 · HER2-positive Breast Cancer
What this study did
NCT07619365 · Washington University School of Medicine
2026-11-30 – 2031-11-30 · Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
NCT04986579 · Dana-Farber Cancer Institute
2021-10-07 – 2030-06-01 · Metastatic Breast Cancer, Chemotherapy-induced Alopecia
What this study did
NCT07825753 · Fudan University
2026-09-10 – 2030-02-01 · Advanced or Metastatic Pancreatic Adenocarcinoma, Advanced or Metastatic Breast Cancer (BC)
What this study did
NCT06832202 · Shanghai Henlius Biotech
2025-04-16 – 2029-12-01 · HER2-low Hormone Receptor Positive Breast Cancer
What this study did
NCT06750484 · Yale University
2025-06-20 – 2028-12-31 · Breast Cancer Metastatic
What this study did
NCT07368543 · Fudan University
2026-01-16 – 2028-12-01 · Metastatic Breast Cancer
What this study did
NCT07497386 · Jiangsu HengRui Medicine Co., Ltd.
2026-04-28 – 2028-12 · Unresectable Locally Recurrent Breast Cancer, Unresectable Locally Metastatic Breast Cancer
What this study did
NCT07203378 · University of Utah
2025-11-04 – 2028-11 · Metastatic Breast Cancer
What this study did
NCT07150208 · Fudan University
2025-10-20 – 2028-09 · Breast Cancer With Brain Metastasis, HER2-low Expressing Breast Cancer
What this study did
NCT07647016 · Fudan University
2026-04-01 – 2028-02-01 · Breast Cancer
What this study did
NCT06486883 · MedSIR
2025-06-30 – 2028-01 · Advanced Breast Cancer, Advanced Breast Carcinoma, Hormone Receptor Positive Breast Carcinoma
What this study did
NCT06409390 · H. Lee Moffitt Cancer Center and Research Institute
2024-08-14 – 2027-04 · Metastatic Breast Cancer
What this study did
NCT06271837 · AstraZeneca
2024-02-22 – 2027-02-10 · Advanced Solid Tumors (Excluding Gastric Cancer and Breast Cancer)
What this study did
NCT06048718 · MedSIR
2024-06-05 – 2026-11 · Breast Cancer, Metastatic Breast Cancer
What this study did
NCT06837792 · Yonsei University
2023-10-01 – 2026-10-01 · Hormone Receptor(HR)-Positive, Low HER2 Advanced Breast Cancer Patients (HER2 IHC 1+ or 2+ & ISH Negative)
What this study did
Non-Small Cell Lung Cancer
NCT07936422 · Centre Leon Berard
2027-02 – 2036-02 · NSCLC (Advanced Non-small Cell Lung Cancer), Urothelial Cancer, Pan-rare Tumor With no T-DXd Approvals, Pan-frequent Tumors With no T-DXd Approvals
What this study did
NCT07662473 · Hunan Province Tumor Hospital
2026-07-29 – 2028-06-30 · NSCLC
What this study did
NCT07428044 · Memorial Sloan Kettering Cancer Center
2026-02-13 – 2027-02-13 · Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II, Non-Small Cell Lung Cancer Stage IIIA, Non-Small Cell Lung Cancer Stage IIIB
What this study did
NCT05246514 · AstraZeneca
2022-07-13 – 2026-12-31 · HER2-mutant Non-Small Cell Lung Cancer
What this study did
NCT06250777 · Yonsei University
2024-07-11 – 2026-12 · Non Small Cell Lung Cancer
What this study did
NCT03334617 · AstraZeneca
2017-12-18 – 2026-09-11 · Non-Small Cell Lung Cancer
What this study did
Other / comorbidity
NCT05408845 · NRG Oncology
2023-03-03 – 2033-07-31 · Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Unresectable Salivary Gland Carcinoma
What this study did
NCT07069712 · AstraZeneca
2025-07-17 – 2029-07-16 · Gastroesophageal Adenocarcinoma
What this study did
NCT06630130 · Jeeyun Lee
2025-01-22 – 2029-06-30 · Stomach Neoplasms
What this study did
NCT07691489 · Memorial Sloan Kettering Cancer Center
2026-10 – 2029-06 · Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum
What this study did
Phase 1/2 (23)
Breast Cancer
NCT04538742 · AstraZeneca
2020-12-28 – 2030-01-31 · Metastatic Breast Cancer
What this study did
NCT07785856 · The Methodist Hospital Research Institute
2026-12 – 2029-12 · T-dxd Resistant HER2-Positive, HER2 Low Metastatic Breast Cancer
What this study did
NCT06324357 · Boehringer Ingelheim
2024-06-28 – 2029-01-08 · Metastatic Breast Cancer, Metastatic Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma, Colorectal Cancer
What this study did
NCT03742102 · AstraZeneca
2018-12-21 – 2027-02-26 · Triple Negative Breast Neoplasms
What this study did
HER2-Positive Breast Cancer
NCT05593094 · Hoffmann-La Roche
2020-09-03 – 2027-08-31 · Advanced Solid Tumors, HER2-positive Breast Cancer
What this study did
NCT05091528 · Silverback Therapeutics
2022-02-08 – 2022-07-07 · HER2-positive Breast Cancer, HER2-positive Gastric Cancer, HER2-positive Colorectal Cancer, HER2-expressing Non-small Cell Lung Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07198724 · Kristina A. Fanucci
2025-11-17 – 2038-06-01 · Metastatic Breast Cancer, HER2 Low Breast Carcinoma, HER2-negative Breast Cancer, Breast Cancer, Breast Cancer Female
What this study did
NCT05868226 · QuantumLeap Healthcare Collaborative
2023-02-15 – 2031-12-30 · HER2-positive Breast Cancer, Metastatic Cancer, Metastatic Breast Cancer, Metastatic, HER2-positive Metastatic Breast Cancer, HER2 Mutation-Related Tumors, HER-2 Protein Overexpression, HER2-negative Breast Cancer, Triple Negative Breast Cancer, HR Positive, Hormone Receptor-positive Breast Cancer, Estrogen Receptor Positive Tumor, Progesterone Receptor-positive Breast Cancer, Hormone Receptor Negative Breast Carcinoma, Solid Tumor, Solid Tumor, Adult, Solid Carcinoma, HER2 Low Breast Cancer, HER2 Low Breast Carcinoma, ER Positive Breast Cancer, PR-positive Breast Cancer, Minimal Residual Disease, Colo-rectal Cancer, Colon Cancer, Rectal Cancer, ctDNA Monitoring, Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms, Neoplasm, Residual, Adenocarcinoma of Colon, Adenocarcinoma
What this study did
NCT03424005 · Hoffmann-La Roche
2018-03-30 – 2030-09-30 · Metastatic Breast Cancer
What this study did
NCT07134153 · Fudan University
2025-05-12 – 2027-06-28 · Breast Cancer
What this study did
NCT04644068 · AstraZeneca
2020-11-12 – 2027-05-28 · Ovarian Cancer, Breast Cancer, Pancreatic Cancer, Prostate Cancer, Additional Indications Below for Module 4 and 5, Non-small Cell Lung Cancer, Colorectal Cancer, Bladder Cancer, Gastric Cancer, Biliary Cancer, Cervical Cancer, Endometrial Cancer, Small Cell Lung Cancer Only in Module 5
What this study did
NCT05824975 · GI Innovation, Inc.
2023-05-30 – 2027-04-24 · Advanced Solid Tumor, Metastatic Solid Tumor, Soft Tissue Sarcoma (STS), Platinum-resistant Ovarian Cancer (PROC), Hepatocellular Carcinoma (HCC), Colorectal Cancer (CRC), HER2 Negative Breast Cancer, Cutaneous Melanoma, Renal Cell Carcinoma (RCC)
What this study did
NCT06328387 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2024-01-29 – 2026-03-01 · Advanced Breast Cancer, Metastatic Breast Cancer
What this study did
Non-Small Cell Lung Cancer
NCT07012031 · National Cancer Institute (NCI)
2026-06-17 – 2027-06-14 · Locally Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
What this study did
Other / comorbidity
NCT06771622 · FBD Biologics Limited
2025-03-13 – 2029-01-01 · Solid Cancer
What this study did
NCT07157956 · Convalife (Shanghai) Co., Ltd.
2025-09-10 – 2028-12-30 · Advanced Solid Tumor
What this study did
NCT06085755 · Jeeyun Lee
2024-09-30 – 2028-12-01 · Stomach Neoplasm
What this study did
NCT06525298 · Eisbach Bio GmbH
2024-09-09 – 2028-12 · Advanced Solid Tumor, Homologous Recombination Deficiency, HRR Deficiency
What this study did
NCT07619521 · National Cancer Institute (NCI)
2027-06-01 – 2028-09-08 · Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Pancreatic Ductal Adenocarcinoma
What this study did
NCT05417594 · AstraZeneca
2022-06-24 – 2028-02-07 · Advanced Solid Malignancies
What this study did
NCT06731803 · Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
2025-03-25 – 2027-12-31 · Esophagogastric Adenocarcinoma
What this study did
NCT05894824 · Yonsei University
2024-02-05 – 2026-01-01 · Gastric Cancer, Gastroesophageal Junction (GEJ) Cancer
What this study did
NCT07529613 · National Cancer Center Hospital East
2023-12-20 – 2025-12-31 · Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma
What this study did
Phase 1 (23)
Breast Cancer
NCT04704661 · National Cancer Institute (NCI)
2021-08-09 – 2027-03-31 · Advanced Breast Carcinoma, Advanced Colon Carcinoma, Advanced Colorectal Carcinoma, Advanced Endometrial Carcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Malignant Solid Neoplasm, Advanced Salivary Gland Carcinoma, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, HER2-Positive Breast Carcinoma, Malignant Hepatobiliary Neoplasm, Metastatic Breast Carcinoma, Metastatic Colon Carcinoma, Metastatic Colorectal Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Salivary Gland Carcinoma, Stage III Colon Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Major Salivary Gland Cancer AJCC v8, Stage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Stage IV Colon Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Major Salivary Gland Cancer AJCC v8, Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8, Unresectable Breast Carcinoma, Unresectable Colon Carcinoma, Unresectable Colorectal Carcinoma, Unresectable Endometrial Carcinoma, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Salivary Gland Carcinoma
What this study did
HER2-Positive Breast Cancer
NCT07454668 · Baptist Health South Florida
2027-01 – 2030-02 · Breast Cancer, HER2-positive Breast Cancer, Brain Metastases, Cancer, Cancer Metastatic
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07553390 · M.D. Anderson Cancer Center
2026-11-05 – 2038-03-30 · Breast Cancer
What this study did
NCT05633979 · M.D. Anderson Cancer Center
2023-02-09 – 2032-12-31 · Breast Cancer
What this study did
NCT06840886 · Pheast Therapeutics
2025-03-31 – 2031-04 · Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma, CNS Tumor, Breast Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma, Carcinosarcoma, Ovarian
What this study did
NCT07137416 · National Cancer Institute (NCI)
2026-10-06 – 2028-01-10 · Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Metastatic HER2-Low Breast Carcinoma, Metastatic HER2-Positive Breast Carcinoma, Metastatic Hormone Receptor-Positive Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Unresectable Breast Carcinoma, Unresectable HER2-Low Breast Carcinoma, Unresectable HER2-Positive Breast Carcinoma, Unresectable Hormone Receptor-Positive Breast Carcinoma, Unresectable Malignant Solid Neoplasm, Unresectable Triple-Negative Breast Carcinoma
What this study did
NCT06331169 · Fudan University
2024-07-31 – 2027-06-30 · Breast Cancer
What this study did
NCT04556773 · AstraZeneca
2020-12-17 – 2027-06-01 · Metastatic Breast Cancer
What this study did
NCT04042701 · Daiichi Sankyo
2020-02-10 – 2027-03-31 · Breast Cancer, Non-small Cell Lung Carcinoma
What this study did
NCT03523572 · Daiichi Sankyo
2018-08-02 – 2023-09-12 · Breast Cancer, Urothelial Carcinoma
What this study did
Non-Small Cell Lung Cancer
NCT04686305 · AstraZeneca
2021-03-09 – 2027-06-30 · Locally Advanced or Metastatic Non-Small Cell Lung Cancer
What this study did
NCT05650879 · Enliven Therapeutics
2023-03-20 – 2026-07 · HER2 Mutant Non-small Cell Lung Cancer, HER2-positive Metastatic Breast Cancer, HER2 Gene Mutation, HER2 Amplification
What this study did
Other / comorbidity
NCT05765851 · Daiichi Sankyo
2023-05-30 – 2031-02-28 · Advanced Solid Tumor
What this study did
NCT07318389 · M.D. Anderson Cancer Center
2026-04-22 – 2029-11-14 · Dynamic Tumor Resistance, Metastatic Colorectal Cancer
What this study did
NCT07015697 · Daiichi Sankyo
2025-07-17 – 2028-12-31 · Recurrent or Metastatic Solid Tumors
What this study did
NCT06244485 · Daiichi Sankyo
2024-02-22 – 2028-11-01 · Advanced Solid Tumor
What this study did
NCT07086768 · Lei Zheng
2026-01-26 – 2028-08-07 · Solid Tumor, Advanced Solid Tumor, Metastatic Solid Tumor
What this study did
NCT05372614 · National Cancer Institute (NCI)
2022-10-05 – 2028-07-17 · Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Unresectable Malignant Solid Neoplasm, Unresectable Pancreatic Adenocarcinoma
What this study did
NCT05274048 · Fox Chase Cancer Center
2022-06-24 – 2028-06 · Gastric Cancer, Gastrointestinal Cancer, HER2 Gene Mutation
What this study did
NCT06364410 · National Cancer Institute (NCI)
2025-02-03 – 2027-07-08 · Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Locally Advanced Gastric Carcinoma, Locally Advanced Gastroesophageal Junction Adenocarcinoma, Locally Advanced Malignant Solid Neoplasm, Metastatic Gastric Carcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Malignant Solid Neoplasm, Unresectable Gastric Carcinoma, Unresectable Gastroesophageal Junction Adenocarcinoma, Unresectable Malignant Solid Neoplasm
What this study did
NCT05614739 · Eli Lilly and Company
2023-01-12 – 2027-06 · Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral Neoplasms
What this study did
NCT04294628 · National Cancer Institute (NCI)
2020-09-01 – 2027-01-19 · Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid Neoplasm, Refractory Malignant Solid Neoplasm, Unresectable Malignant Solid Neoplasm
What this study did
NCT04585958 · National Cancer Institute (NCI)
2021-05-21 – 2026-12-31 · Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid Neoplasm
What this study did
Phase 4 (5)
Breast Cancer
NCT05376878 · City of Hope Medical Center
2022-12-21 – 2027-04-27 · Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain
What this study did
NCT06245824 · Cancer Institute and Hospital, Chinese Academy of Medical Sciences
2024-01-30 – 2026-12-01 · Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07195344 · Institut Claudius Regaud
2025-10-15 – 2029-10 · Locally Advanced or Metastatic Breast Cancers
What this study did
NCT07162259 · Yan Xue
2025-10-01 – 2027-12-31 · Breast Neoplasms
What this study did
NCT06429761 · AstraZeneca
2025-01-02 – 2026-10-31 · BREAST CANCER
What this study did
Early phase / not applicable (6)
HR+/HER2- Metastatic Breast Cancer
NCT07130344 · Centre Paul Strauss
2025-09 – 2030-09 · Metastatic Breast Cancer, HER 2 Low-expressing Breast Cancer
What this study did
NCT07782086 · Shuangyue Liu
2026-09-07 – 2029-12 · Breast Cancer
What this study did
NCT07281001 · Blokhin's Russian Cancer Research Center
2025-12 – 2026-05 · HER2-positive Breast Cancer, Trastuzumab Deruxtecan
What this study did
NCT05919212 · Fondazione Policlinico Universitario Agostino Gemelli IRCCS
2023-02-01 – 2026-02-01 · Metastatic Breast Cancer
What this study did
Other / comorbidity
NCT04257162 · SOLTI Breast Cancer Research Group
2019-12-13 – 2028-05 · Metastatic Cancer
What this study did
Used as active comparator (7)

Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07060807 · Merck Sharp & Dohme LLC
2025-07-21 – 2033-07-14 · Breast Neoplasms
What this study did
Phase 2/3 (1)
Breast Cancer
NCT07294508 · Shanghai Henlius Biotech
2026-02-27 – 2030-12-30 · HER2 + Breast Cancer
What this study did
Phase 2 (5)
HER2-Positive Breast Cancer
NCT07416253 · Henan Cancer Hospital
2026-03 – 2030-07 · Breast Cancer
What this study did
NCT07417241 · Peking University Cancer Hospital & Institute
2026-03-31 – 2029-12-31 · Breast Cancer, HER2-positive Breast Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07630103 · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
2026-06 – 2031-12 · Advanced Breast Cancer
What this study did
NCT07678957 · Sichuan Baili Pharmaceutical Co., Ltd.
2026-08-31 – 2028-12 · Breast Cancer
What this study did
NCT06102824 · Guangdong Provincial People's Hospital
2024-10-01 – 2028-06-30 · HER2-negative Breast Cancer, Advanced Breast Cancer
What this study did
Appears in other studies (5)

Studies that reference this drug without giving it an intervention arm of its own: other formulations' programs, background therapy, or registry-search bleed.

Phase 3 (1)
HR+/HER2- Metastatic Breast Cancer
NCT07543536 · Sun Yat-sen University
2026-06-08 – 2031-04-01 · Advanced/Metastatic Breast Cancer, HER2+, Low, or Ultralow Advanced/Metastatic Breast Cancer
What this study did
Phase 2 (2)
Breast Cancer
NCT04553770 · Jonsson Comprehensive Cancer Center
2020-10-09 – 2026-12-31 · Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer
What this study did
HER2-Positive Breast Cancer
NCT07152782 · Fudan University
2025-09-24 – 2031-11 · Breast Cancer With Brain Metastasis, HER2-positive Breast Cancer
What this study did
Phase 1/2 (2)
HER2-Positive Breast Cancer
NCT06253871 · Iambic Therapeutics, Inc
2024-03-25 – 2028-12 · HER2 Mutation-Related Tumors, HER2, HER2-positive Breast Cancer, HER2 + Breast Cancer, Brain Metastases From Solid Tumors, Brain Metastases From HER2 and Breast Cancer, CNS Metastases, HER2-Positive Solid Tumors, NSCLC (Non-small Cell Lung Cancer), HER2-positive Bladder Cancer, HER2-positive Colorectal Cancer, HER2 + Gastric Cancer, HER2-positive Gastroesophageal Cancer
What this study did
HR+/HER2- Metastatic Breast Cancer
NCT07701941 · Daiichi Sankyo
2026-09-17 – 2032-05-01 · Hormone Receptor Positive, HER2-low or HER2-ultralow, Unresectable or Metastatic Breast Cancer
What this study did

Competitive landscape

This mechanism is crowded: 16 other tracked programmes target it, none of them ahead of this one.

This drug's own stage for Non-Small Cell Lung Cancer: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Trastuzumab Deruxtecan: this drugApprovedAntibody–drug conjugateHER2Weak signal
NCT04644237: Percentage of Participants With Confirmed Objective Response Rate by Blinded Independent Central Review Following Intravenous Administration of Trastuzumab Deruxtecan in Participants With Metastatic Non-small Cell Lung Cancer (9 months after the last participant is randomized to data cut off, up to approximately 21 months): Trastuzumab Deruxtecan 5.4 mg/kg 50% (95% CI 39.9 to 60.1) | Trastuzumab Deruxtecan 6.4 mg/kg 56% (95% CI 41.3 to 70)
Adagrasib (Krazati)ApprovedSmall moleculeKRAS G12CPartial signalFeatured results are non-efficacy only in this race
Afatinib (Gilotrif)ApprovedSmall moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01121393: Progression-free Survival (Tumour assessment were performed at screening, week 6, 12, 18, 24, 30, 36, 42, 48 and then every 12 weeks until progression or death whichever occurs first up to week 168): Afatinib 40 Milligram (mg) 11.01 months (95% CI 9.66 to 13.73) vs Gemcitabine / Cisplatin Chemotherapy 5.59 months (95% CI 4.67 to 6.7)
NCT01523587: Progression-free Survival, Based on Central Independent Review as Determined by Response Evaluation Criteria in Solid Tumours 1.1 (First treatment administration up until cut off date of 02 March 2015 (up to 1058 days).): Afatinib 2.63 Months (95% CI 2 to 2.86) vs Erlotinib 1.94 Months (95% CI 1.87 to 2.1)
Alectinib (Alecensa)ApprovedSmall moleculeALKPartial signal
NCT02838420: Investigator-assessed progression-free survival: hazard ratio 0.22 (95% CI 0.13 to 0.38; p<0.0001), median not estimable with alectinib vs 11.1 months with crizotinib (ALESIA primary analysis, Lancet Respir Med 2019).
NCT02604342: Progression-Free Survival (PFS) Using Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Investigator (Randomization to first documented disease progression, death from any cause, or study end (up to 33 months)): Experimental: Alectinib 10.9 months (95% CI 8.1 to 15.5) vs Active Comparator: Premetrexed/Docetaxel 1.4 months (95% CI 1.2 to 1.6)
Alymsys (bevacizumab-Maly)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
AmivantamabApprovedMultispecific antibodyEGFR x c-METPartial signal
NCT04487080: Progression-free survival by blinded independent central review (MARIPOSA, primary endpoint): amivantamab + lazertinib (Arm A, n=429) median 23.72 months (95% CI 19.12 to 27.66) vs osimertinib (Arm B, n=429) 16.59 months (95% CI 14.78 to 18.46); hazard ratio 0.70 (95% CI 0.58 to 0.85), log-rank p = 0.0002. ClinicalTrials.gov posted results.
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
AtezolizumabApprovedMonoclonal antibodyPD-L1Partial signal
NCT03456063: IRF-assessed EFS, stage IIB-IIIB EGFR/ALK wild-type: HR 0.77 (95% CI 0.58-1.02), log-rank p=0.0704 missed
NCT02366143: Progression Free Survival (PFS), as Determined by the Investigator in Arm B Versus Arm C in the Teff-high WT Population and ITT-WT Population (Baseline until disease progression or death, whichever occurs first until data cut-off on 15 September 2017 (up to approximately 29 months)): Arm B (Atezolizumab+Bevacizumab+Paclitaxel + Carboplatin) — Teff-high WT Population: 11.3 Months (95% CI 9.1 to 13); ITT-WT Population: 8.3 Months (95% CI 7.7 to 9.8) vs Arm C (Bevacizumab+Paclitaxel+Carboplatin) — Teff-high WT Population: 6.8 Months (95% CI 5.9 to 7.4); ITT-WT Population: 6.8 Months (95% CI 6 to 7.1)
BAT1706 (Avzivi)ApprovedMonoclonal antibodyVEGF-APartial signal
NCT03329911: Overall response rate at week 18: 48.0% BAT1706 vs 44.5% EU-bevacizumab; risk ratio 1.08 (90% CI 0.94 to 1.24) and risk difference 0.03 (95% CI -0.04 to 0.11), both inside the pre-specified equivalence margins (Cancer Med 2023).
BevacizumabApprovedMonoclonal antibodyVEGF-A, Vascular Endothelial Growth Factor InhibitorPartial signal
NCT00806923: Progression-free survival: HR 0.75 (95% CI 0.64-0.87; P=0.0003) for bevacizumab 7.5 mg/kg + cisplatin/gemcitabine vs placebo + cisplatin/gemcitabine, and HR 0.85 (95% CI 0.73-1.00; P=0.0456) for bevacizumab 15 mg/kg vs placebo
NCT00021060: Overall survival, paclitaxel-carboplatin plus bevacizumab (n=434) vs paclitaxel-carboplatin alone (n=444): median 12.3 vs 10.3 months, hazard ratio for death 0.79, P = 0.003 (Sandler et al., NEJM 2006).
Bevacizumab-Awwb (MVASI)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT01966003: Objective response rate (central independent blinded review, RECIST v1.1), ABP 215 (bevacizumab-awwb, n=328) vs bevacizumab (n=314): 39.0% vs 41.7%; risk ratio 0.93 (2-sided 90% CI 0.80 to 1.09), inside the prespecified equivalence margin of 0.67 to 1.5 (CT.gov posted results).
BinimetinibApprovedSmall moleculeMEK1/2Weak signalNo reviewed efficacy summary in this indication
BrigatinibApprovedSmall moleculeALKPartial signal
NCT03596866: Progression-free Survival (PFS) as Assessed by Blinded Independent Review Committee (BIRC) Per RECIST v1.1 (Up to 33.8 months): Brigatinib 19.253 months vs Alectinib 19.187 months missed
NCT02737501: Progression-free Survival (PFS) (Up to end of study (Up to 56 months)): Randomized Phase: Brigatinib 90 mg QD/180 QD 24.016 months (95% CI 18.46 to 43.2) vs Randomized Phase: Crizotinib 250 mg BID 11.072 months (95% CI 9.13 to 13.01)
CapmatinibApprovedSmall moleculeMETWeak signal
NCT04427072: Progression-free Survival (PFS) Per Blinded Independent Review Committee (BIRC) Using RECIST v1.1 (From randomization to the date of first documented progression or death from any cause, whichever came first, assessed up to approximately 21 months): Capmatinib 6.1 months (95% CI 1.61 to 13.77) vs Docetaxel 4.1 months
NCT02414139: Overall response rate by independent review, single-arm cohorts: treatment-naive with MET mutation 68.3% (95% CI 55 to 79.7); pre-treated with MET mutation 44% (34.1 to 54.3); pre-treated MET copy number >= 10 29% (18.7 to 41.2); copy number < 4 6.7% (0.8 to 22.1).
CemiplimabApprovedMonoclonal antibodyPD-1Partial signal
NCT03088540: Overall Survival (OS) (Up to 94 months): Cemiplimab 23.4 months (95% CI 19.4 to 27.6) vs Chemotherapy 13.7 months (95% CI 11.2 to 16.2)
NCT03409614: Part 1: Overall Survival (OS) (Up to a maximum of 82.2 months): Part 1: Cemiplimab + Chemotherapy 15.9 months (95% CI 11.7 to 24.2) | Part 1: Cemiplimab+AbbrevChemo+Ipilimumab 20.1 months (95% CI 13.7 to 28.3) vs Part 1: Chemotherapy 13.9 months (95% CI 10 to 17.7)
CeritinibApprovedSmall moleculeALKPartial signal
NCT01828099: Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1)
NCT01828112: Progression Free Survival (PFS) Per Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause up to approximately 24 months): Ceritinib 5.4 months (95% CI 4.1 to 6.9) vs Chemotherapy 1.6 months (95% CI 1.4 to 2.8)
CrizotinibApprovedSmall moleculeALK, ROS1, MET/HGFR, and RONPartial signal
NCT01639001: Progression-Free Survival (PFS) Based on IRR by Treatment Arm (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (whichever occurred first, assessed up to 33 months)): Crizotinib 11.1 Months (95% CI 8.3 to 12.6) vs Chemotherapy 6.8 Months (95% CI 5.7 to 7)
NCT01154140: Progression-Free Survival (PFS) Based on IRR (Randomization to objective progression, death or last tumor assessment without progression before any additional anti-cancer therapy (up to 35 months)): Crizotinib 10.9 months (95% CI 8.3 to 13.9) | Chemotherapy 7 months (95% CI 6.8 to 8.2)
DabrafenibApprovedSmall moleculeBRAF V600E/V600K/V600D (also wild-type BRAF/CRAF)Weak signal
NCT04452877: Objective response rate (central and investigator assessment): 75% (95% CI 50.9-91.3%). Disease control rate (central independent review): 95% (95% CI 75.1-99.9%).
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
Dacomitinib PF-00299804
ApprovedUS marketing discontinued
Small moleculeEGFR/HER1, HER2, HER4Partial signal
NCT01774721: Progression Free Survival (PFS) Based on Independent Radiologic Central (IRC) Review (Day 28 of Cycle 1, Cycle 2 then every 8 weeks until disease progression or death due to any cause, whichever occurred first (up to 48 months)): Dacomitinib 14.7 months (95% CI 11.1 to 16.6) vs Gefitinib 9.2 months (95% CI 9.1 to 11)
NCT01000025: Overall Survival (42 Months): PF-00299804 6.83 Months (95% CI 6.08 to 7.49) vs Placebo 6.31 Months (95% CI 5.32 to 7.52) missed
Datopotamab DeruxtecanApprovedAntibody–drug conjugateTROP2Partial signal
NCT04656652: Dual primaries vs docetaxel: progression-free survival 4.4 vs 3.7 months (hazard ratio 0.75; 95% CI 0.62 to 0.91; P=.004); overall survival 12.9 vs 11.8 months (hazard ratio 0.94; 95% CI 0.78 to 1.14; P=.530) (TROPION-Lung01, J Clin Oncol 2025).
NCT04484142: Percentage of Participants With Objective Response Rate (ORR) Based on Blinded Independent Central Review (BICR) (From baseline until disease progression, death, or other protocol defined reason, up to approximately 24 months.): Dato DXd 6.0 mg/kg Q3W 35.8% (95% CI 27.8 to 44.4)
Docetaxel (Taxotere)ApprovedSmall moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
DurvalumabApprovedMonoclonal antibodyPD-L1Reliable signal
NCT02125461: Progression Free Survival Based on Blinded Independent Central Review (BICR) According to Response Evaluation Criteria in Solid Tumors (RECIST 1.1) (Tumor scans performed at baseline then every ~8 weeks up to 48 weeks, then every ~12 weeks thereafter until confirmed disease progression. Assessed until 13 Feb 2017 DCO; up to a maximum of approximately 3 years.): Durvalumab (MEDI4736) 16.8 Months (95% CI 13 to 18.1) vs Placebo 5.6 Months (95% CI 4.6 to 7.8)
NCT03519971: Progression-Free Survival (PFS) (Tumour scans performed at screening, 16 weeks ±1 week after randomization, then every 8 weeks ±1 week up to 48 weeks, and then every 12 weeks ±1 week thereafter until confirmed PD. Assessed up to the DCO date (a maximum of approximately 1988 days).): Durvalumab + SoC CRT 13.8 months (95% CI 9.5 to 16.9) vs Placebo + SoC CRT 9.4 months (95% CI 7.5 to 16.6) missed
EncorafenibApprovedSmall moleculeBRAF V600EWeak signal
NCT03915951: Percentage of Participants With Confirmed Objective Response (OR) as Determined by Independent Radiology Review (IRR) (From date of the first dose of study intervention until documented progressive disease (PD) or start of new anticancer therapy (up to 36 months)): Treatment-Naive 74.6% (95% CI 61.6 to 85) | Previously Treated 46.2% (95% CI 30.1 to 62.8)
Ensartinib (Ensacove)ApprovedSmall moleculeALKPartial signal
NCT02767804: eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001.
EntrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
ErlotinibApprovedSmall moleculeEGFRPartial signal
NCT00446225: Primary endpoint, progression-free survival: hazard ratio 0.42 (95% CI 0.27 to 0.64), p=0.0001, erlotinib vs platinum doublet chemotherapy in EGFR-mutant NSCLC (CT.gov posted results).
GefitinibApprovedSmall moleculeEGFRPartial signal
NCT00020709: Overall survival (maintenance phase, SWOG S0023): median survival 23 months with gefitinib (n=118) vs 35 months with placebo (n=125), two-sided P=.013 missed
Gemcitabine
ApprovedUS marketing discontinued
Small moleculeribonucleotide reductase / DNA polymerase (dCTP competition)Partial signal
NCT00003589: Median overall survival: paclitaxel-cisplatin (arm A) 8.1 months vs gemcitabine-cisplatin (arm B) 8.9 months vs paclitaxel-gemcitabine (arm C) 6.7 months; response rates 31.8% / 36.6% / 27.7% respectively
IpilimumabApprovedMonoclonal antibodyCTLA-4 antagonistPartial signal
NCT01285609: Median overall survival: 13.37 months with ipilimumab plus paclitaxel/carboplatin (95% CI 11.76 to 14.78) vs 12.42 months with placebo plus paclitaxel/carboplatin (95% CI 11.6 to 13.63). missed
Jobevne (bevacizumab-Nwgd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
LarotrectinibApprovedSmall moleculeTRK (TRKA/TRKB/TRKC, encoded by NTRK1/NTRK2/NTRK3 gene fusions)not yet gradedNo reviewed efficacy summary in this indication
LazertinibApprovedSmall moleculeEGFRPartial signal
NCT04487080: Progression-Free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death whichever occurs first (up to 32.8 months)): Experimental: Arm A (Open-label): Amivantamab + Lazertinib 23.72 Months (95% CI 19.12 to 27.66) | Experimental: Arm C (Double-blind): Lazertinib+Placebo Matching Osimertinib 18.46 Months (95% CI 14.75 to 20.11) vs Active Comparator: Arm B (Double-blind): Osimertinib+Placebo Matching Lazertinib 16.59 Months (95% CI 14.78 to 18.46)
NCT04988295: Main Study: Progression-free Survival (PFS) According to Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 as Assessed by Blinded Independent Central Review (BICR) (From randomization to either disease progression or death, whichever occurred first (up to 1 year 7 months)): Main Study: Arm A: Lazertinib + Amivantamab + Carboplatin + Pemetrexed (LACP/ACP-L) 8.31 months (95% CI 6.77 to 9.1) | Main Study: Arm C: Amivantamab + Carboplatin + Pemetrexed (ACP) 6.28 months (95% CI 5.55 to 8.41) vs Main Study: Arm B: Carboplatin + Pemetrexed (CP) 4.17 months (95% CI 4.04 to 4.44)
LorlatinibApprovedSmall moleculeALK / ROS1Partial signalNo reviewed efficacy summary in this indication
Nab-PaclitaxelApprovedSmall moleculeMicrotubulesPartial signal
NCT00540514: Percentage of Participants Who Achieved an Objective Confirmed Complete Response or Partial Response by Blinded Radiology Assessment (Objective response was evaluated every 6 weeks until progression or new anti-cancer therapy initiation, up to 22 months.): Albumin-bound Paclitaxel + Carboplatin 33% (95% CI 28.6 to 36.7) vs Paclitaxel + Carboplatin 25% (95% CI 21.2 to 28.5)
NecitumumabApprovedMonoclonal antibodyEpidermal growth factor receptor (EGFR)Partial signal
NCT00981058: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31 Months)): Necitumumab + Gemcitabine + Cisplatin 11.5 Months (95% CI 10.4 to 12.6) vs Gemcitabine + Cisplatin 9.9 Months (95% CI 8.9 to 11.1)
NCT00982111: Overall Survival Time (OS) (Randomization to Death from Any Cause (Up to 31.6 Months)): Necitumumab + Pemetrexed + Cisplatin 11.3 Months (95% CI 9.5 to 13.4) vs Pemetrexed + Cisplatin 11.5 Months (95% CI 10.1 to 13.1) missed
NivolumabApprovedMonoclonal antibodyPD-1Partial signal
NCT01673867: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 413 deaths, up to March 2015 (approximately 29 months)): Nivolumab 12.19 Months (95% CI 9.66 to 14.98) vs Docetaxel 9.36 Months (95% CI 8.05 to 10.68)
NCT01642004: Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint (Randomization until 199 deaths, up to November 2014, approximately 25 months): Nivolumab 9.23 months (95% CI 7.33 to 13.27) vs Docetaxel 6.01 months (95% CI 5.13 to 7.33)
Opdivo QvantigApprovedMonoclonal antibodyPD-1not yet gradedNo reviewed efficacy summary in this indication
Osimertinib (Tagrisso)ApprovedSmall moleculeEGFRPartial signal
NCT02151981: Progression Free Survival (PFS) by Investigator Assessment (RECIST tumour assessments every 6 weeks from randomisation until objective disease progression up to 19 months (at the time of the primary PFS analysis).): Osimertinib 80mg 10.1 Months (95% CI 8.3 to 12.3) | Chemotherapy 4.4 Months (95% CI 4.2 to 5.6)
PembrolizumabApprovedMonoclonal antibodyPD-1Partial signal
NCT02142738: Progression Free Survival (PFS) Rate at Month 6 (Month 6): Pembrolizumab 62.1% (95% CI 53.8 to 69.4) vs SOC Chemotherapy 50.3% (95% CI 41.9 to 58.2)
NCT01905657: Overall Survival (OS) (Through pre-specified database cutoff date of 30 Sep 2015 (Up to approximately 24 months)): Pembrolizumab 2 mg/kg — Strongly PD-L1 Positive: 14.9 Months; All PD-L1 Positive: 10.4 Months (95% CI 9.4 to 11.9) | Pembrolizumab 10 mg/kg — Strongly PD-L1 Positive: 17.3 Months; All PD-L1 Positive: 12.7 Months (95% CI 10 to 17.3) vs Docetaxel 75 mg/m^2 — Strongly PD-L1 Positive: 8.2 Months (95% CI 6.4 to 10.7); All PD-L1 Positive: 8.5 Months (95% CI 7.5 to 9.8)
Pembrolizumab Berahyaluronidase Alfa (Keytruda Qlex)ApprovedMonoclonal antibodyPD-1Partial signalFeatured results are non-efficacy only in this race
Pemetrexed (Alimta)ApprovedSmall moleculeThymidylate synthase (TS), dihydrofolate reductase (DHFR), GARFTPartial signal
NCT00789373: Investigator-assessed Objective Progression-free Survival (PFS) (Date of randomization to the date of measured PD or date of death from any cause (up to 19.3 months)): Pemetrexed + Cisplatin Followed by Maintenance Pemetrexed 4.11 months (95% CI 3.15 to 4.57) | Pemetrexed + Cisplatin Followed by Placebo 2.83 months (95% CI 2.6 to 3.12)
NCT00102804: Progression-Free Survival (PFS) Time (Randomization to measured PD or death from any cause (up to 41 months)): Pemetrexed and BSC 4.27 months (95% CI 4.07 to 4.73) | Placebo and BSC 2.6 months (95% CI 1.68 to 2.83)
Porfimer SodiumApprovedSmall moleculePhotoactivated radicalsWeak signalFeatured results are safety and non-efficacy only in this race
PralsetinibApprovedSmall moleculeRETPartial signal
NCT04222972: Arm A vs Arm B: Treatment Period: Progression-free Survival (PFS) (Up to approximately 50 months): Arm B: Treatment Period- Pralsetinib 18.7 months (95% CI 11.1 to 25.2) vs Arm A: Treatment Period- SOC 9 months (95% CI 7.1 to 11.5)
NCT03037385: Phase 2 confirmed overall response rate by blinded central review (RECIST 1.1), pralsetinib 400 mg once daily, single arm: RET fusion-positive NSCLC after platinum 63.1% (95% CI 54.2 to 71.4; n=130); treatment-naive RET fusion-positive NSCLC 78.3% (95% CI 69.2 to 85.7; n=106).
RamucirumabApprovedMonoclonal antibodyVEGFR2Partial signal
NCT05633602: Pragmatica-Lung (NCT05633602), primary endpoint overall survival: ramucirumab plus pembrolizumab median OS 10.1 months vs SOC 10.0 months; HR 1.04 (95% CI 0.88-1.22); p=.66. missed
NCT01168973: Overall survival: ramucirumab plus docetaxel 10.5 months vs placebo plus docetaxel 9.1 months (HR 0.86, 95% CI 0.75-0.98; p=0.023), n=1253 (Garon et al., Lancet 2014, REVEL).
RepotrectinibApprovedSmall moleculeROS1/NTRKnot yet gradedNo reviewed efficacy summary in this indication
Rybrevant Faspro (amivantamab And Hyaluronidase-Lpuj)ApprovedMultispecific antibodyEGFR x c-METnot yet gradedNo reviewed efficacy summary in this indication
Selpercatinib (Retevmo)ApprovedSmall moleculeRETPartial signal
NCT04819100: Investigator-assessed event-free survival, stage II-IIIA (primary): 2-year EFS 92% with selpercatinib vs 61% with placebo; HR 0.17 (95% CI 0.06 to 0.51), P<0.001 (Wu et al., N Engl J Med 2026)
NCT04194944: PFS by blinded independent central review (pembrolizumab-eligible population): median 24.84 months with selpercatinib (95% CI 16.89 to not estimable) vs 11.17 months with platinum-pemetrexed plus pembrolizumab (95% CI 8.77 to 16.76); HR 0.465 (95% CI 0.309 to 0.699), p=0.0002
Sevabertinib (Hyrnuo)ApprovedSmall moleculeEGFR/HER2Weak signalNo reviewed efficacy summary in this indication
SotorasibApprovedSmall moleculeKRAS G12CPartial signal
NCT04303780: Progression-free Survival (PFS) (Baseline up to primary analysis data cut-off date (02 August 2022); max time on study as of primary analysis data cut off was 24.3 months): AMG 510 5.62 months (95% CI 4.27 to 7.75) vs Docetaxel 4.47 months (95% CI 3.02 to 5.68)
NCT03600883: NSCLC cohort (FDA label section 14, single arm): objective response rate 36% (95% CI 28 to 45) by blinded independent central review in 124 patients given sotorasib 960 mg once daily; complete response 2%, partial response 35%; median duration of response 10 months (range 1.3+ to 11.1); 58% of responders had a response lasting 6 months or more.
Sunvozertinib (Zegfrovy)ApprovedSmall moleculeEGFRnot yet gradedNo reviewed efficacy summary in this indication
TaletrectinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Tecentriq Hybreza (atezolizumab And Hyaluronidase-Tqjs)ApprovedMonoclonal antibodyPD-L1Partial signalNo reviewed efficacy summary in this indication
Telisotuzumab VedotinApprovedAntibody–drug conjugateMETnot yet gradedNo reviewed efficacy summary in this indication
Tepotinib (Tepmetko)ApprovedSmall moleculeMETWeak signal
NCT02864992: ORR by independent review 46% (95% CI 36–57) in 99 patients with at least 9 months of follow-up; median duration of response 11.1 months
TrametinibApprovedSmall moleculeMEK1/2Partial signal
NCT01336634: Overall Response Rate (ORR) (From study treatment start date until first documented complete response or partial response, assessed up to approximately 50 months): Cohort A (Dabrafenib Monotherapy) 27/78 | Cohort B - Double Combination (Dabrafenib+Trametinib) mBRAF V600E: DAB 150MG BID, TRA 2mG QD 39/57 | Cohort C - Double Combination (Dabrafenib+Trametinib) Naive mBRAF V600E: DAB 150MG BID, TRA 2mG QD 23/36 | Crossover - Double Combination (Dabrafenib+Trametinib): DAB 150MG BID, TRA 2mG QD 4/20
TremelimumabApprovedMonoclonal antibodyCTLA-4Partial signal
NCT02453282: Overall Survival (OS); PD-L1 (TC >=25%) Analysis Set Population, Durvalumab Monotherapy Vs SoC Chemotherapy and Durvalumab + Tremelimumab Vs SoC Chemotherapy (From baseline (Day 1, Week 0) until death due to any cause, assessed up to the data cut-off date (a maximum of approximately 3 years).): Durvalumab + Tremelimumab 11.9 months (95% CI 9 to 17.7) vs Durvalumab Monotherapy 16.3 months (95% CI 12.2 to 20.8) | SoC Chemotherapy 12.9 months (95% CI 10.5 to 15) missed
NCT02352948: Overall Survival (OS) (From randomization (Day 1) until death due to any cause, approximately 36 months): Sub-study B: Durvalumab+Tremelimumab 11.5 months (95% CI 8.7 to 14.1) vs Sub-study A: Durvalumab 11.7 months (95% CI 8.2 to 17.4) | Sub-study A: SoC 6.8 months (95% CI 4.9 to 10.2) | Sub-study B: SoC 8.7 months (95% CI 6.5 to 11.7) missed
Vegzelma (bevacizumab-Adcd)ApprovedMonoclonal antibodyVEGF-Anot yet gradedNo reviewed efficacy summary in this indication
Zenocutuzumab (Bizengri)ApprovedMultispecific antibodyHER2; HER3 (blocks NRG1 binding to HER3)not yet gradedNo reviewed efficacy summary in this indication
ZidesamtinibApprovedSmall moleculeROS1not yet gradedNo reviewed efficacy summary in this indication
Zirabev (bevacizumab-Bvzr)ApprovedMonoclonal antibodyVEGF-AReliable signal
NCT02364999: Objective Response Rate (ORR) by Week 19 (25 weeks): PF-06439535 45.3% (95% CI 40.01 to 50.57) vs Bevacizumab-EU 44.6% (95% CI 39.4 to 49.89)
Zongertinib (Hernexeos)ApprovedSmall moleculeHER2 Mutant-selectivenot yet gradedNo reviewed efficacy summary in this indication
7MW3711Phase 3Antibody–drug conjugateB7-H3not yet gradedNo reviewed efficacy summary in this indication
Beruzatatug PelitecanPhase 3Antibody–drug conjugateHER3not yet gradedNo reviewed efficacy summary in this indication
CPO301Phase 3Antibody–drug conjugateEGFRnot yet gradedNo reviewed efficacy summary in this indication
Izalontamab BrengitecanPhase 3Antibody–drug conjugateEGFR + HER3not yet gradedNo reviewed efficacy summary in this indication
Patritumab DeruxtecanPhase 3Antibody–drug conjugateHER3Weak signal
NCT05865990: LMD cohort primary endpoint met: 3-month OS rate 65% (Kaplan-Meier estimate 69.6%, 95% CI 52.0-93.2, P < 0.001)
PyrotinibPhase 3Small moleculeEGFR/HER1, HER2, HER4Partial signalNo reviewed efficacy summary in this indication
Sacituzumab GovitecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05089734: EVOKE-01 (NCT05089734), primary endpoint overall survival: sacituzumab govitecan 11.1 months vs docetaxel 9.8 months; not statistically significant missed
Sacituzumab TirumotecanPhase 3Antibody–drug conjugateTROP2Partial signal
NCT05870319: OptiTROP-Lung04 (NCT05870319), primary endpoint median PFS: sacituzumab tirumotecan 8.3 months vs chemotherapy 4.3 months; HR 0.49; p<0.0001
Trastuzumab BrengitecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
Trastuzumab RezetecanPhase 3Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
UtidelonePhase 3Small moleculeTubulin / microtubulesPartial signal
NCT03693547: Primary endpoint ORR 15.4% (95% CI 4.4%-34.9%) in ITT (N = 26); 19.0% (95% CI 5.4%-41.9%) in per-protocol (N = 21)
Docetaxel (HB1801)Phase 2/3Small moleculeMicrotubules (tubulin)not yet gradedNo reviewed efficacy summary in this indication
ChidamidePhase 2Small moleculeHDACWeak signal
NCT05068427: Objective response rate: 6.7% (2/30); disease control rate 50%; median PFS 3.5 months (95% CI 1.9-5.5). Trial stopped early for futility against an expected ORR of 24%. missed
Denosumab (Xgeva)Phase 2Monoclonal antibodyRANKLPartial signalFeatured results are non-efficacy only in this race
Disitamab VedotinPhase 2Antibody–drug conjugateHER2Weak signalNo reviewed efficacy summary in this indication
HRS-4508Phase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
JS207Phase 2Multispecific antibodyPD-1 + VEGFAnot yet gradedNo reviewed efficacy summary in this indication
NeratinibPhase 2Small moleculeEGFR/HER2Partial signal
NCT00266877: Objective response rate (primary endpoint): 3% in arm A (prior TKI, EGFR-mutation positive, n=91), 0% in arm B (prior TKI, EGFR wild-type, n=48), 0% in arm C (TKI-naive, n=28); 3 of 4 patients with exon 18 G719X EGFR mutation had a partial response missed
PrifetrastatPhase 2Small moleculeKAT6A / KAT6Bnot yet gradedNo reviewed efficacy summary in this indication
TucatinibPhase 2Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
ZanidatamabPhase 2Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
177Lu-DWJ155Phase 1RadiopharmaceuticalHER2not yet gradedNo reviewed efficacy summary in this indication
BBO-10203Phase 1Small moleculeRAS:PI3Kα protein-protein interactionnot yet gradedNo reviewed efficacy summary in this indication
BL-M17D1Phase 1Antibody–drug conjugateHER2not yet gradedNo reviewed efficacy summary in this indication
KJ015Phase 1Multispecific antibodyHER2not yet gradedNo reviewed efficacy summary in this indication
MT-304
Phase 1(overall)
RNA / oligonucleotideHER2not yet gradedNo reviewed efficacy summary in this indication
NVL-330Phase 1Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication
RAD202
Phase 1(overall)
RadiopharmaceuticalHER2
not yet graded(overall)
No reviewed efficacy summary in this indication
GSK6855547
—(overall)
Small moleculeHER2not yet gradedNo reviewed efficacy summary in this indication

Large race: only the 88 furthest-along competitors are listed; 523 more exist in this indication but aren't shown. Use the search box to compare against any of them.

Upcoming events

(101 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Trastuzumab Deruxtecan to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2026 (4)
November 2026 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2026-11 · NCT06048718 · CT.gov ↗
What to watch
December 2026 (3)
Phase 2Non-Small Cell Lung CancerEnrolling by invitation
Est. primary completion 2026-12 · NCT06250777 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2026-12-31 · NCT06331169 · CT.gov ↗
What to watch
Phase 1Metastatic Malignant Solid Neoplasm, Platinum-Resistant Ovarian High Grade Serous Adenocarcinoma, Unresectable Malignant Solid NeoplasmRecruiting
Est. primary completion 2026-12-31 · NCT04585958 · CT.gov ↗
What to watch
2027 (43)
January 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01 · NCT06486883 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2027-01-15 · NCT06797622 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-01-30 · NCT07134153 · CT.gov ↗
What to watch
February 2027 (1)
Phase 2HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2027-02-10 · NCT06271837 · CT.gov ↗
What to watch
March 2027 (3)
Phase 2Gastric Cancer, HER2-positive Gastric CancerRecruiting
Est. primary completion 2027-03-01 · NCT06253650 · CT.gov ↗
What to watch
Phase 2Part 1: Bladder, Biliary Tract, Cervical, Endometrial, Ovarian, Pancreatic Cancer, Rare Tumors, Any Tumor Type Excluding Breast, Gastric …Active not recruiting
Est. primary completion 2027-03-23 · NCT04482309 · CT.gov ↗
What to watch
Phase 1Breast CancerActive not recruiting
Est. primary completion 2027-03-31 · NCT04704661 · CT.gov ↗
What to watch
April 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-04 · NCT06409390 · CT.gov ↗
What to watch
Phase 2Breast CancerActive not recruiting
Est. primary completion 2027-04 · NCT06172127 · CT.gov ↗
What to watch
Phase 4Breast CancerRecruiting
Est. primary completion 2027-04-27 · NCT05376878 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-04-30 · NCT05900206 · CT.gov ↗
What to watch
May 2027 (4)
Phase 2Colorectal Cancer, Resectable Colorectal CarcinomaRecruiting
Est. primary completion 2027-05 · NCT05845450 · CT.gov ↗
What to watch
Phase 3Breast CancerActive not recruiting
Est. primary completion 2027-05-03 · NCT04784715 · CT.gov ↗
What to watch
Phase 2Gastric CancerActive not recruiting
Est. primary completion 2027-05-04 · NCT04379596 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerActive not recruiting
Est. primary completion 2027-05-28 · NCT04644068 · CT.gov ↗
What to watch
June 2027 (6)
Phase 1Gastric Cancer, Gastrointestinal Cancer, HER2 Gene MutationRecruiting
Est. primary completion 2027-06 · NCT05274048 · CT.gov ↗
What to watch
Phase 1Urinary Bladder Neoplasms, Neoplasm Metastasis, Ureteral NeoplasmsRecruiting
Est. primary completion 2027-06 · NCT05614739 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-06-01 · NCT06832202 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-06-01 · NCT07368543 · CT.gov ↗
What to watch
Phase 1/2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-14 · NCT07012031 · CT.gov ↗
What to watch
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-06-30 · NCT04686305 · CT.gov ↗
What to watch
July 2027 (1)
Phase 1Clinical Stage III Gastric Cancer AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8 …Recruiting
Est. primary completion 2027-07-08 · NCT06364410 · CT.gov ↗
What to watch
August 2027 (2)
Phase 1Solid Tumor, Advanced Solid Tumor, Metastatic Solid TumorRecruiting
Est. primary completion 2027-08-07 · NCT07086768 · CT.gov ↗
What to watch
Phase 1/2Breast CancerActive not recruiting
Est. primary completion 2027-08-31 · NCT05593094 · CT.gov ↗
What to watch
September 2027 (4)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-09 · NCT07150208 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-09-01 · NCT07825753 · CT.gov ↗
What to watch
Phase 2Brain Cancer, Glioblastoma, Metastatic Cancer, Leptomeningeal Metastasis, Recurrent GlioblastomaRecruiting
Est. primary completion 2027-09-22 · NCT06058988 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-09-30 · NCT07393425 · CT.gov ↗
What to watch
October 2027 (4)
Phase 2Prostate Cancer Metastatic, Prostate Cancer, CRPCRecruiting
Est. primary completion 2027-10 · NCT06610825 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-10-01 · NCT05982678 · CT.gov ↗
What to watch
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-10-01 · NCT05950945 · CT.gov ↗
What to watch
Phase 2Colorectal Cancer, Colorectal Adenocarcinoma, Rectal Adenocarcinoma, Rectal Cancer, Adenocarcinoma, Rectal Cancer, Metastatic …Recruiting
Est. primary completion 2027-10-20 · NCT07407465 · CT.gov ↗
What to watch
November 2027 (3)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-11 · NCT07203378 · CT.gov ↗
What to watch
Phase 2Gastroesophageal AdenocarcinomaRecruiting
Est. primary completion 2027-11-09 · NCT07069712 · CT.gov ↗
What to watch
Phase 1Dynamic Tumor Resistance, Metastatic Colorectal CancerRecruiting
Est. primary completion 2027-11-14 · NCT07318389 · CT.gov ↗
What to watch
December 2027 (8)
Phase 1/2Stomach NeoplasmActive not recruiting
Est. primary completion 2027-12-01 · NCT06085755 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2027-12-01 · NCT05795101 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2027-12-30 · NCT07647016 · CT.gov ↗
What to watch
Phase 1/2Esophagogastric AdenocarcinomaActive not recruiting
Est. primary completion 2027-12-31 · NCT06731803 · CT.gov ↗
What to watch
Phase 2Lymphoma, Non-Hodgkin, Multiple Myeloma, Advanced Solid TumorsRecruiting
Est. primary completion 2027-12-31 · NCT02693535 · CT.gov ↗
What to watch
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07662473 · CT.gov ↗
What to watch
Phase 2Desmoplastic Small Round Cell Tumor, Osteosarcoma, Recurrent Desmoplastic Small Round Cell Tumor, Recurrent Kidney Wilms Tumor …Recruiting
Est. primary completion 2027-12-31 · NCT04616560 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2027-12-31 · NCT07162259 · CT.gov ↗
What to watch
2028 (29)
January 2028 (4)
Phase 1/2Solid CancerActive not recruiting
Est. primary completion 2028-01-01 · NCT06771622 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-01-01 · NCT06733233 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-01 · NCT06533826 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-01-10 · NCT07137416 · CT.gov ↗
What to watch
February 2028 (2)
Phase 1/2Advanced Solid MalignanciesRecruiting
Est. primary completion 2028-02-07 · NCT05417594 · CT.gov ↗
What to watch
Phase 3Advanced Cancer, Metastatic CancerRecruiting
Est. primary completion 2028-02-17 · NCT06174987 · CT.gov ↗
What to watch
March 2028 (2)
Phase 2Gastric Adenocarcinoma, Gastroesophageal Junction AdenocarcinomaActive not recruiting
Est. primary completion 2028-03-31 · NCT05034887 · CT.gov ↗
What to watch
Phase 2Advanced Malignant Solid Neoplasm, Metastatic Malignant Solid NeoplasmRecruiting
Est. primary completion 2028-03-31 · NCT06311214 · CT.gov ↗
What to watch
May 2028 (1)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-05-15 · NCT07905313 · CT.gov ↗
What to watch
June 2028 (5)
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06 · NCT07497386 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT07198724 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-06-01 · NCT04986579 · CT.gov ↗
What to watch
Phase 3Gastric Cancer, Gastroesophageal Junction CancerRecruiting
Est. primary completion 2028-06-01 · NCT06731478 · CT.gov ↗
What to watch
Phase 3Biliary Tract CancerRecruiting
Est. primary completion 2028-06-12 · NCT06467357 · CT.gov ↗
What to watch
July 2028 (3)
Phase 2Salivary Gland Carcinoma, Precision TherapyRecruiting
Est. primary completion 2028-07-10 · NCT06145308 · CT.gov ↗
What to watch
Phase 1Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2028-07-17 · NCT05372614 · CT.gov ↗
What to watch
Phase 2Metastatic Salivary Gland Carcinoma, Recurrent Salivary Gland Carcinoma, Stage III Major Salivary Gland Cancer AJCC v8 …Recruiting
Est. primary completion 2028-07-31 · NCT05408845 · CT.gov ↗
What to watch
August 2028 (1)
Phase 1/2Advanced Solid TumorNot yet recruiting
Est. primary completion 2028-08-12 · NCT07157956 · CT.gov ↗
What to watch
September 2028 (2)
Phase 1/2Advanced Solid Tumor, Homologous Recombination Deficiency, HRR DeficiencyRecruiting
Est. primary completion 2028-09 · NCT06525298 · CT.gov ↗
What to watch
Phase 1/2Advanced Pancreatic Ductal Adenocarcinoma, Metastatic Pancreatic Ductal Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8 …Recruiting
Est. primary completion 2028-09-08 · NCT07619521 · CT.gov ↗
What to watch
October 2028 (2)
Phase 2Stomach NeoplasmsRecruiting
Est. primary completion 2028-10-30 · NCT06630130 · CT.gov ↗
What to watch
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2028-10-30 · NCT07836257 · CT.gov ↗
What to watch
November 2028 (3)
Phase 1Advanced Solid TumorActive not recruiting
Est. primary completion 2028-11-01 · NCT06244485 · CT.gov ↗
What to watch
Phase 2HER2 Positive Newly Diagnosed Metastatic Esophageal, Gastric, GEJ Cancer Patients With an ECOG Performance Status of 2Not yet recruiting
Est. primary completion 2028-11-01 · NCT07126561 · CT.gov ↗
What to watch
Phase 3Ovarian CancerRecruiting
Est. primary completion 2028-11-01 · NCT06819007 · CT.gov ↗
What to watch
December 2028 (4)
Phase 1/2Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07785856 · CT.gov ↗
What to watch
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2028-12 · NCT07130344 · CT.gov ↗
What to watch
Phase 1Recurrent or Metastatic Solid TumorsRecruiting
Est. primary completion 2028-12-31 · NCT07015697 · CT.gov ↗
What to watch
Phase 2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2028-12-31 · NCT06750484 · CT.gov ↗
What to watch
2029 (11)
January 2029 (2)
Phase 1/2Breast CancerRecruiting
Est. primary completion 2029-01-08 · NCT06324357 · CT.gov ↗
What to watch
Phase 3Endometrial CancerRecruiting
Est. primary completion 2029-01-19 · NCT06989112 · CT.gov ↗
What to watch
February 2029 (1)
Phase 1Breast CancerNot yet recruiting
Est. primary completion 2029-02 · NCT07454668 · CT.gov ↗
What to watch
April 2029 (2)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-04 · NCT06840886 · CT.gov ↗
What to watch
Phase 3HER2-positive Gastric Cancer, Gastroesophageal Junction AdenocarcinomaRecruiting
Est. primary completion 2029-04-27 · NCT06764875 · CT.gov ↗
What to watch
May 2029 (1)
Phase 1Advanced Solid TumorRecruiting
Est. primary completion 2029-05-31 · NCT05765851 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Colorectal Cancer, Adenocarcinoma of the Colon, Adenocarcinoma of the RectumNot yet recruiting
Est. primary completion 2029-06 · NCT07691489 · CT.gov ↗
What to watch
July 2029 (1)
Early phase / not applicableHR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2029-07 · NCT07782086 · CT.gov ↗
What to watch
August 2029 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2029-08-01 · NCT07371585 · CT.gov ↗
What to watch
October 2029 (2)
Phase 2Breast CancerNot yet recruiting
Est. primary completion 2029-10 · NCT07151586 · CT.gov ↗
What to watch
Phase 4HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2029-10 · NCT07195344 · CT.gov ↗
What to watch
2030 (11)
February 2030 (1)
Phase 3Endometrial CancerRecruiting
Est. primary completion 2030-02-26 · NCT07022483 · CT.gov ↗
What to watch
March 2030 (2)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03-04 · NCT07459673 · CT.gov ↗
What to watch
Phase 2Breast CancerRecruiting
Est. primary completion 2030-03-30 · NCT06439693 · CT.gov ↗
What to watch
April 2030 (1)
Phase 3Non-Small Cell Lung CancerRecruiting
Est. primary completion 2030-04-24 · NCT06899126 · CT.gov ↗
What to watch
June 2030 (1)
Phase 2Breast CancerRecruiting
Est. primary completion 2030-06 · NCT05704829 · CT.gov ↗
What to watch
July 2030 (1)
Phase 3HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-07-04 · NCT07683754 · CT.gov ↗
What to watch
September 2030 (1)
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-09-30 · NCT03424005 · CT.gov ↗
What to watch
November 2030 (1)
Phase 2HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-11-30 · NCT07619365 · CT.gov ↗
What to watch
December 2030 (3)
Phase 3HR+/HER2- Metastatic Breast CancerNot yet recruiting
Est. primary completion 2030-12-20 · NCT07828054 · CT.gov ↗
What to watch
Phase 1/2HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2030-12-30 · NCT05868226 · CT.gov ↗
What to watch
Phase 1HR+/HER2- Metastatic Breast CancerActive not recruiting
Est. primary completion 2030-12-31 · NCT05633979 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3Breast CancerRecruiting
Est. primary completion 2032-05-31 · NCT07578116 · CT.gov ↗
What to watch
2033 (1)
February 2033 (1)
Phase 2Non-Small Cell Lung CancerNot yet recruiting
Est. primary completion 2033-02 · NCT07936422 · CT.gov ↗
What to watch
2036 (1)
March 2036 (1)
Phase 1HR+/HER2- Metastatic Breast CancerRecruiting
Est. primary completion 2036-03-30 · NCT07553390 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(3)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

27 October 2026ApprovalEU approves Enhertu as adjuvant monotherapy in HER2-positive early breast cancer
EU, EC · Source ↗
14 September 2026Topline resultDESTINY-Lung04: Enhertu met its PFS primary endpoint vs pembrolizumab plus chemotherapy
AstraZeneca; Daiichi Sankyo · Source ↗
1 September 2026ApprovalEnhertu with pertuzumab approved in the EU for first-line HER2-positive metastatic breast cancer
EU, EC/EMA · Source ↗